WO1999061412A1 - Derives d'acide hydroxamique et utilisation medicinale de ces derives - Google Patents
Derives d'acide hydroxamique et utilisation medicinale de ces derives Download PDFInfo
- Publication number
- WO1999061412A1 WO1999061412A1 PCT/JP1999/002631 JP9902631W WO9961412A1 WO 1999061412 A1 WO1999061412 A1 WO 1999061412A1 JP 9902631 W JP9902631 W JP 9902631W WO 9961412 A1 WO9961412 A1 WO 9961412A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- phenyl
- alkyl
- title compound
- integer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- X represents hydrogen or a protecting group for a hydroxyl group
- R 1 is hydrogen, alkyl, ⁇ reel alkyl, Heteroari one thio alkyl, ⁇ Li - thio alkyl, alkylthioalkyl, ⁇ reel alkylthioalkyl, full Tarui Mi bendingukiru, alkenyl or a (CH 2) L, - A [1 1 And A is selected from N, O, and S as an additional heteroatom at a position which is not adjacent to the bonded N atom.
- R 2 represents hydrogen, alkyl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl or aryl, which may be a 5- or 6-membered N-hetero ring which may be
- R 3 is hydrogen, alkyl or formula
- Q 1 represents an aromatic hydrocarbon ring or an aromatic hetero ring
- m represents an integer of 0 to 3
- R 13 represents hydrogen, halogen, Hydroxyl group, nitro, cyano, trifluoromethyl, lower alkyl, alkoxy, alkylthio, formyl, acyloxy, phenyl, arylalkyl, carboxy, one COO Ra (Ra indicates lower alkyl, arylalkyl or aryl), Moubare, Guanidino, Hydroxinolehoninoleoxy, S / Reho, Alienolealkyloxyalkyl or
- r represents a group selected from R (wherein n and q may be the same or different, and each represents 1 to 5 indicates an integer of, r is indicates an integer of 0 to 2, R 1 4 and R 1 5 may be the same or different, are each hydrogen, alkyl, ⁇ Li Ruarukiru, heteroalkyl ⁇ reel alkyl Or R 14 and R 14 and R 15 may be taken together with an adjacent nitrogen atom to form an optionally substituted heterocycle, and R 16 is an aryl, heteroaryl, or Represents hydroxysulfonyloxy or sulfo, and R 17 represents a hydroxyl group, hydroxysulfonyloxy, sulfo E or carboxy))
- Q 2 represents an aromatic hydrocarbon ring or an aromatic hetero ring
- R 18 represents hydrogen, halogen, hydroxyl, nitro, cyano, trifluoromethyl, low Grade anolequil, alekoxy, alkylthio, e / leminole, ash / reoxy, phenyl, arylealkyl, carboxy, —COO Ra (Ra stands for lower alkyl, arylealkyl or aryle), diurebamoyl, guanidino, hydroxysulfoninele Sai Kishi, Su / Reho, Ali,
- R 19 and R 2 ° may be the same or different, and each represents hydrogen, alkyl, aryl, R 19 and R 2 ° together with an adjacent nitrogen atom may form a substituted or unsubstituted heterocycle; 21 shows Ariru, Heteroariru, hydroxycarboxylic sulfonyl Okishi, sulfo or carboxy, R 22 represents a hydroxyl group, hydroxycarboxylic sulfonyl Okishi, sulfo or carboxy)].
- R 3 is the formula (A)
- Q 1 represents a benzene ring
- m represents an integer of 0 to 3
- R 13 represents guanidino, hydroxysulfonyloxy, sulfo or
- R 14 and R 15 may be the same or different, Represents hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl, respectively, or R 14 and R 15 together with an adjacent nitrogen atom form a heterocycle which may be substituted R 16 may be hydroxysulfonyloxy
- R 19 and R 2 ° may be the same or different, and each represents hydrogen or alkyl.
- ⁇ reel alkyl indicates Heteroariru or Ariru, or R 1 9 Contact and R 2 Q may form a hetero cycle to which may be connexion substitutions together with the adjacent nitrogen atom
- R 21 is Ariru, Represents a group selected from heteroaryl, hydroxysulfonyloxy, sulfo or carboxy), or Q 2 represents a furan ring, and R 18 represents arylalkyloxyalkyl or
- R 19 and R 2 ° are the same Or different, each representing hydrogen, alkyl, arylalkyl, heteroaryl or aryl, or R 19 and R 2 ° together with an adjacent nitrogen atom be substituted to good may form a hetero cycle
- R 2 2 is a hydroxyl group, hydroxycarboxylic sulfonyl O alkoxy, a group represented by a group selected from sulfo or an carboxy
- arylalkyl, heteroarylthioalkyl, arylthioalkyl, arylalkylthioalkyl, phthalimidalkyl, aryl, heteroaryl and heteroarylalkyl may have a substituent. Or a pharmacologically acceptable salt thereof.
- R 3 has the formula (A)
- Q 1 represents a benzene ring
- m represents an integer of 0 to 3
- R 13 represents guanidino, hydroxysulfonyloxy, sulfo or
- n represents an integer of 1 to 5
- r represents an integer of 0 to 2
- R 14 and R 15 may be the same or different and each represents hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl, or R 14 and R 15 are taken together with the adjacent nitrogen atom
- R 16 represents hydroxysulfonyloxy or sulfo
- Y is furyl, chenyl, pyrrolyl, or pyridyl.
- R 19 and R 2 ° may be the same or different and each represents alkyl
- R 3 is an alkyl or It is
- R 19 and R 2 ° may be the same or different, and each represents hydrogen or alkyl.
- Arylalkyl, heteroaryl or aryl, or R 19 and R 2 ° together with an adjacent nitrogen atom may form an optionally substituted heterocycle;
- R 21 is aryl, Represents a group selected from heteroaryl, hydroxysulfonyloxy, sulfo or carboxy), or Q 2 represents a furan ring, and R 18 represents arylalkyloxyalkyl or
- s and t may be the same or different, and each of 1 to 5
- R 19 and R 2 ° may be the same or different and each represents hydrogen, alkyl, arylalkyl, heteroaryl or aryl. Or R 19 and R 2 ° may form a heterocycle which may be substituted with an adjacent nitrogen atom, and R 22 may be a hydroxyl group, a hydroxysulfonyloxy, a sulfo or a carboxy group.
- R 13 is guanidino, hydroxysulfonyloxy or
- hydroxamic acid derivative or a pharmaceutically acceptable salt thereof according to claim 2 wherein the hydroxamic acid derivative is selected from the group consisting of 1,3,4,4_trimethyl-1-f midazolidinyl) methylhexanohydroxamic acid.
- R 3 is, Guanijino, human Dorokishisu Honinoreokishi, sulfo, R
- n represents an integer of 1 to 5
- r represents an integer of 0 to 2
- R 14 and R 15 may be the same or different, and each represents hydrogen, alkyl, ⁇ reel alkyl, hetero ⁇ reel an alkyl or Ariru, or R 14 and R 15 may form a Terosaiku Le to which may be connexion substitutions together with the adjacent nitrogen atom
- R 16 is heat Dorokishi 3.
- R 11 represents hydrogen, anoalkyl, arylalkyl, heteroarylalkyl or aryl
- R 2 represents hydrogen, alkyl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl or aryl,
- R 3 is hydrogen, alkyl or formula
- Q 1 represents an aromatic hydrocarbon ring or an aromatic hetero ring
- m represents an integer of 0 to 3
- R 13 represents hydrogen, halogen, or a hydroxyl group.
- r represents a group selected from R (wherein n and q may be the same or different, and each represents 1 to 5 And r represents an integer of 0 to 2, and R 14 and R 15 may be the same or different and each represents hydrogen, alkyl, arylalkyl, heteroarylalkyl or And R 14 and R 15 may be taken together with the adjacent nitrogen atom to form an optionally substituted heterocycle, and R 16 may be an aryl, heteroaryl, or hydroxysulfonyloxy. Or sulfo, R 17 is hydroxyl, hydroxysulfonyloxy, sulfo
- Q 2 represents an aromatic hydrocarbon ring or an aromatic hetero ring
- R 18 represents hydrogen, halogen, hydroxyl, nitro, cyano, trifluoromethyl, lower Alkyl, alkoxy, alkylthio, formyl, asiloxy, phenyl, arylalkyl, carboxy, COO Ra (Ra indicates lower alkyl, arylalkyl or aryl), carbamoyl, guanidino, hydroxysulfonyloxy, sulfo, arylalkyl Xyalkyl or
- R 19 and R 2 ° may be the same or different, and each represents hydrogen, alkyl, aryl, R 19 and R 2 ° together with an adjacent nitrogen atom may form an optionally substituted heterocycle;
- R 21 represents aryl, alkyl or heteroarylalkyl or aryl.
- Heteroariru, hydroxycarboxylic sulfonyl Okishi shows a sulfo or carboxy,
- R 22 represents a hydroxyl group, hydroxycarboxylic sulfonyl Okishi, sulfo or carboxy)].
- R 3 is the formula (A)
- Q 1 represents a benzene ring
- m represents an integer of 0 to 3
- R 13 represents guanidino, hydroxysulfonyloxy, sulfo or
- R 14 and R 15 may be the same or different, Represents hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl, respectively, or R 14 and R 15 together with an adjacent nitrogen atom form a heterocycle which may be substituted R 16 may be hydroxysulfonyloxy
- R 19 and R 2 may be the same or different, and each represents hydrogen, alkyl, R 19 and R 2 ° together with an adjacent nitrogen atom may form a heterocyclic cycle, R 21 and R 2 ° may be substituted with an adjacent nitrogen atom;
- Q 2 represents a furan ring, and
- R 18 represents arylalkyloxyalkyl or
- R 19 and R 2 ° are the same. others may be different, are each hydrogen, alkyl, ⁇ reel alkyl, hetero Ariru or indicates Ariru, or R 19 and R 2 ° hetero cycle to optionally substituted turned nitrogen atom and one cord adjacent R 22 represents a group selected from the group consisting of hydroxyl, hydroxysulfonyloxy, sulfo and carboxy).
- arylalkyl, heteroarylthioalkyl, arylthioalkyl, arylalkylthioalkyl, phthalimidalkyl, aryl, heteroaryl and heteroarylalkyl may have a substituent.
- R 3 has the formula (A)
- Q 1 represents a benzene ring
- m represents any integer from 0 to 3
- R 13 represents guanidino, hydroxysulfonyloxy, sulfo or
- R 14 and R 15 may be the same or different, their respective hydrogen, alkyl, ⁇ reel alkyl, shows a hetero ⁇ reel alkyl or ⁇ Li Lumpur, or R 14 and R 15 form a hetero cycle to which may be connexion substitutions together with the adjacent nitrogen atom R 16 represents hydroxysulfonyloxy or sulfo))), and Y is furyl, phenyl, pyrenyl, pyridyl, thiazolyl, phenyl, alkoxyphenyl, Or — NR 19 R 20 (wherein R 19 and R 2 ° may be the same or different and each represents an alkyl), or (ii) R 3 is alkyl or
- R 19 and R 2 ° may be the same or different, and each represents hydrogen or alkyl.
- Arylalkyl, heteroaryl or aryl, or R 19 and R 2 ° together with an adjacent nitrogen atom may form an optionally substituted heterocycle
- R 21 is Aryl, heteroaryl, hydroxysulfonyloxy, sulfo or carboxy
- Q 2 represents a furan ring
- R 18 represents arylalkyloxyalkyl or
- R 19 and R 2 ° are the same. others may be different, are each hydrogen, alkyl, ⁇ reel alkyl, hetero Ariru or indicates Ariru, or R 19 and R 2 ° hetero cycle to optionally substituted turned nitrogen atom and one cord adjacent R 22 represents a hydroxyl group, hydroxysulfonyloxy, sulfo or carboxy)
- a pharmaceutical composition comprising the hydroxamic acid derivative according to any one of claims 1 to 7 or a pharmacologically acceptable salt thereof, and a pharmacologically acceptable carrier.
- composition according to claim 10 which is a TNF ⁇ production inhibitor.
- the present invention relates to a novel hydroxamic acid derivative or a pharmacologically acceptable salt thereof. More specifically, the present invention relates to a hydroxamic acid derivative or a pharmacologically acceptable salt thereof which is useful as a production inhibitor of tumor necrosis factor (TNF ⁇ ). The present invention also relates to a novel intermediate compound useful for synthesizing the above hydroxamic acid derivative.
- TNF ⁇ tumor necrosis factor
- TNF alpha TNF alpha and, while known as widely involved cytokines on activation of biological defense and immune mechanisms during inflammatory, its sustained and excessive production, multiple organ failure: represented ( ⁇ OF multiple organ failure) It is also known to be a factor that causes and hates various diseases associated with organ damage.
- MOFs are used during multiple major invasions (post major surgery, severe trauma, burns, acute knee inflammation, severe infectious diseases, etc.) during the course of multiple lung, heart, kidney, It is understood as a dysfunction that appears simultaneously or continuously in important organs. MOF has a poor prognosis in proportion to the number of dysfunctional organs and has a very high mortality rate, but its treatment has not yet been established. .
- Matrix Metal Tanno II an enzyme responsible for processing from membrane-bound TNF to free TNF.
- Click protease inhibitor (MMP matrix metalloproteinase) is endotoxin (LPS: lipopolysaccharide) specifically inhibit the secretion of free T NF alpha stimulation has been reported to exhibit a life-saving effect (e.g., McGeehan , GM et al. Ature 370: p.558-561 (1994);).
- the present invention has been made based on the above background art, and an object of the present invention is to provide a novel hydroxamic acid derivative or a pharmacologically acceptable salt thereof useful as a TNF production inhibitor. It is in.
- Another object of the present invention is to provide a novel intermediate compound useful for the synthesis of the compound.
- Still another object of the present invention is to provide a novel TNF ⁇ production inhibitor useful as a medicament.
- the present invention relates to the following (1) to (11).
- X represents hydrogen or a protecting group for a hydroxyl group
- R 1 is hydrogen, alkyl, arylalkyl, heteroarylthioalkyl, arylthioalkyl, alkylthioalkyl, arylalkylthioalkyl, phthalimidalkyl, alkenyl, or 1 (CH 2 ), -A [1 A is any integer from 1 to 4, wherein A is ( a ) linked by an N atom, and (b) selected from N, O and S as a further heteroatom at a position not adjacent to the bonded N atom.
- R 2 is hydrogen, anoalkyl, arylalkyl, hetero Indicates arylalkyl, cycloalkyl, cycloalkyl, or aryl,
- R 3 is hydrogen, alkyl or formula
- Q 1 represents an aromatic hydrocarbon ring or an aromatic hetero ring
- m represents an integer of 0 to 3
- R 13 represents hydrogen, halogen, Hydroxyl group, nitrite, cyano, trifluoromethyl, lower alkyl, alkoxy, alkylthio, honolemil, asinole xy, feninole, aryla / lekir, canolepoxy, COO Ra (Ra is lower alkyl, arylalkyl or aryl) Indicate), Ruba Moinore, Guanidino, Hydroxys / Lefoninoleoxy, Snorejo, Arinoleanolequinoleoxyalkyl or
- r represents a group selected from R (wherein n and q may be the same or different and each represents 1 to 5 Represents any integer, r represents any integer from 0 to 2, and R 14 and R 15 may be the same or different and each represents hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl.
- R 14 and R 15 may be taken together with an adjacent nitrogen atom to form an optionally substituted heterocycle
- R 16 is aryl, heteroaryl, hydroxysulfonyl indicates Okishi or sulfo
- R 17 represents a hydroxyl group, hydroxycarboxylic sulfonyl O carboxymethyl, Sulfathiazole e or carboxy)]
- Q 2 represents an aromatic hydrocarbon ring or an aromatic hetero ring
- R 18 is hydrogen, halogen, hydroxyl, nitro, cyano, trifluoromethyl, lower alkyl.
- R 19 and R 2 ° may be the same or different and represent hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl, respectively, or R 19 and R 2 ° together with the adjacent nitrogen atom May form a substituted or unsubstituted heterocycle
- R 21 represents aryl, heteroaryl, hydroxysulfonyloxy, sulfo or carboxy
- R 22 represents a hydroxyl group, hydroxysulfonyloxy. , Sulfo or carboxy)).
- R 3 is the formula (A)
- Q 1 represents a benzene ring
- m represents an integer of 0 to 3
- R 13 represents guanidino, hydroxysulferoxy, sulfo or
- n represents an integer of 1 to 5
- r represents an integer of 0 to 2
- R 14 and R 15 may be the same or different, their respective hydrogen, alkyl, ⁇ reel alkyl, shows a hetero ⁇ reel alkyl or ⁇ Li Lumpur, or R 14 and R 15 a together with the adjacent nitrogen atom connexion May form an optionally substituted heterocycle, and R 16 represents hydroxysulfonyloxy or sulfo)) or a group represented by
- R 19 and R 2Q may be the same or different, and each represents hydrogen, alkyl, Represents arylalkyl, heteroaryl or aryl, or R 19 and R 2 may be taken together with an adjacent nitrogen atom to form an optionally substituted heterocycle, and R 21 is aryl, heteroaryl, Represents a group selected from the group consisting of hydroxysulfonyloxy, sulfo and carboxy), or Q 2 represents a furan ring, and R 18 represents arylalkyloxyalkyl or
- s and t may be the same or different, each represents an integer of 1 to 5, u represents an integer of 0 to 2, R 19 and R 2 G are the same.
- Each represents hydrogen, alkyl, arylalkyl, heteroaryl or aryl, or R 19 and R 2 ° may be substituted together with an adjacent nitrogen atom. May form a heterocycle, and R 22 represents a hydroxyl group, hydroxysulfonyloxy, sulfo or carboxy)
- arylalkyl, heteroarylthioalkyl, arylthioalkyl, arylalkylthioalkyl, phthalimidalkyl, aryl, heteroaryl and heteroarylalkyl may have a substituent. Or a pharmacologically acceptable salt thereof.
- R 3 has the formula (A)
- Q 1 represents a benzene ring
- m represents an integer of 0 to 3
- R 13 represents guanidino, hydroxysulfoninoleoxy, sulfo or
- (CH 2 ) n —— represents a group selected from R (wherein, n represents an integer of 1 to 5, r represents an integer of 0 to 2, R 14 and R 15 may be the same or different, their respective hydrogen, alkyl, ⁇ reel alkyl, shows a hetero ⁇ reel alkyl or ⁇ Li Lumpur, or R 14 and R 15 a together with the adjacent nitrogen atom connexion And R 16 represents hydroxysulfonyloxy or sulfo)), and Y represents furyl, chenyl, pyrrolyl, pyridyl, or the like. Thiazolyl, phenyl, alkoxyphenyl, or NR 19 R 20 wherein R 19 and R 2 ° may be the same or different and each represents an alkyl, or (ii) R 3 is alkyl or
- R 19 and R 2 ° may be the same or different, and each represents hydrogen or alkyl.
- ⁇ reel alkyl, Heteroari indicates Ichiru or Ariru, or R 19 Contact and R 2 ° may form a terrorist cycles to which may be connexion substitutions together with the adjacent nitrogen atom,
- R 21 is Aryl, heteroaryl, hydroxysulfonylo
- X 2 represents a furan ring
- R 18 represents arylalkyloxyalkyl
- R 19 and R 2 ° are the same. others may be different, are each hydrogen, alkyl, ⁇ reel alkyl, hetero Ariru or indicates Ariru, or R 19 and R 2 ° hetero cycle to optionally substituted turned nitrogen atom and one cord adjacent
- R 22 represents a group selected from the group consisting of hydroxyl, hydroxysulfonyloxy, sulfo and carboxy), or a group represented by the formula (1): Pharmacologically acceptable salts.
- R 13 in the formula (A) is guanidino, hydroxysulfonyloxy or a formula
- R 3 is guadino, hydroxysulfonyloxy, sulfo,
- n represents an integer of 1 to 5
- r represents an integer of 0 to 2
- R 14 and R 15 may be the same or different, and are each hydrogen, alkyl, ⁇ reel alkyl, hetero ⁇ reel an alkyl or Ariru, or R 14 and R 15 may form a Terosaiku Le to which may be connexion substitutions together with the adjacent nitrogen atom
- R 16 is heat Dorokishi
- Equation (II)
- R 11 is hydrogen, ', aryl, heteroaryl
- R 12 is
- A is (a) linked by an N atom, and (b) at least one member selected from N, O and S as a further heteroatom at a position not adjacent to the bonded N atom.
- R 2 represents hydrogen, alkyl, arylalkyl, heteroaryl, cycloalkyl, cycloalkylalkyl or aryl,
- R 3 is hydrogen, alkyl or formula
- Q 1 represents an aromatic hydrocarbon ring or an aromatic hetero ring
- m represents an integer of 0 to 3
- R 13 represents hydrogen, halogen, or a hydroxyl group.
- (CH 2 ) n —— (O—— (CH 2 ) C —) represents a group selected from r R (wherein n and q may be the same or different, and each represents 1 to 5 Represents any integer, r represents an integer from 0 to 2, R 14 and R 15 may be the same or different and each represents hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl. Or R 14 and R 15 may be taken together with an adjacent nitrogen atom to form an optionally substituted heterocycle, and R 16 may be aryl, heteroaryl, hydroxysulfonyloxy or sulfo. R 17 represents a hydroxyl group, hydroxysulfonyloxy, sulfo or carboxy))],
- Q 2 represents an aromatic hydrocarbon ring or an aromatic hetero ring
- R 18 is hydrogen, halogen, hydroxyl, nitro, cyano, trifluoromethyl, lower alkyl.
- (CH 2 ) mi-(0— (CH 2 ) t- ) represents a group selected from U R, wherein s and t may be the same or different, and each of them is any of! And u represents an integer of 0 to 2, and R 19 and R 2 may be the same or different and are each hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl. Or R 19 and R 2 ° together with an adjacent nitrogen atom may form an optionally substituted heterocycle, and R 21 is aryl, heteroaryl, hydroxysulfonyloxy. shows a sulfo or carboxy, R 22 represents a hydroxyl group, hydroxycarboxylic sulfonyl Okishi, sulfo or carboxy)].
- R 3 is the formula (A)
- Q 1 represents a benzene ring
- m represents any integer from 0 to 3
- R 13 represents guanidino, hydroxysulfonyloxy, sulfo or
- n represents an integer of 1 to 5
- r represents an integer of 0 to 2
- R 14 and R 15 May be the same or different and each represents hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl, or R 14 and R 15 are substituted together with the adjacent nitrogen atom
- R 16 represents hydroxysulfonyloxy or sulfo
- R 19 and R 2 ° may be the same or different, and each represents hydrogen, kill, ⁇ reel alkyl indicates Heteroariru or Ariru, or R 1 9 Contact and R 2 ° may form a hetero cycle to which may be connexion substitutions together with the adjacent nitrogen atom, R 2 1 is Aryl, heteroaryl, hydroxysulfonyloxy, sulfo or carboxy) or Q 2 represents a furan ring, and R 18 represents arylalkyloxyalkyl or
- R 19 and R 2 ° are the same Or may be different and represent hydrogen, alkyl, arylalkyl, heteroaryl or aryl, respectively, or R 19 and R 2 ° may be substituted together with an adjacent nitrogen atom may form a hetero cycle, R 2 2 is a hydroxyl group, hydroxycarboxylic sulfonyl O alkoxy, a group selected from sulfo or an carboxy)
- arylalkyl, heteroarylthioalkyl, arylthioalkyl, arylalkylthioanolequinole, phthalimidalkyl, aryl, heteroaryl and heteroarylalkyl may have a substituent. (Hereinafter referred to as intermediate compound (II)).
- R 3 is the formula (A)
- Q 1 represents a benzene ring
- m represents any integer from 0 to 3
- R 13 represents guanidino, hydroxysulfonyloxy, sulfo or
- R 14 and R 15 may be the same or different, their respective hydrogen, alkyl, ⁇ reel alkyl, shows a hetero ⁇ reel alkyl or ⁇ Li Lumpur, or R 14 and R 15 form a hetero cycle to which may be connexion substitutions together with the adjacent nitrogen atom
- R 16 represents hydroxysulfonyloxy or sulfo)
- Y is furyl, phenyl, phenyl, pyridyl, thiazolyl, phenyl, alkoxyphenyl, or NR 19 R
- R 19 and R 2 ° may be the same or different and each represents an alkyl, or (ii) R 3 is alkyl or
- R 19 and R 2 ° may be the same or different, and each represents hydrogen or alkyl.
- ⁇ reel alkyl indicates Heteroariru or Ariru
- R 19 Contact and R 2 ° may form a hetero cycle to which may be connexion substitutions together with the adjacent nitrogen atom
- R 21 is Ariru, Heteroariru The hydroxysulfonylo
- R 19 and R 2 ° are the same.
- R 22 represents a hydroxyl group, hydroxycarboxylic sulfonyl O alkoxy, the compound of a group represented by a group selected from sulfo or an carboxy)
- a pharmaceutical composition comprising the hydroxamic acid derivative or the pharmaceutically acceptable salt thereof according to any of the above (:!) To (7), and a pharmacologically acceptable carrier.
- the alkyl moiety is preferably an alkyl moiety having 1 to 6 carbon atoms which may be linear or branched, and the aryl moiety preferably having a phenyl, naphthyl or ortho-fused bicyclic group. And 8 to 10 ring atoms and at least one ring is an aromatic ring (for example, indenyl and the like).
- the heteroarylthioalkyl represented by R 1 and R 12 is preferably such that the alkyl portion thereof is preferably a straight-chain or branched-chain having 1 to 6 carbon atoms, and the heteroaryl portion is preferably a carbon atom and 5- to 6-membered ring groups having 1 to 4 heteroatoms (oxygen, sulfur or nitrogen), or 8 to 10 ring atoms derived therefrom, ortho-fused bicyclic heteroaryls, especially benzene Examples include a benzo derivative fused to a ring, a derivative derived by fusing a propenylene, trimethylene or tetramethylene group thereto, and a stable N-oxide thereof.
- heteroaryl moiety examples include pyrrolyl, pyrrolinyl, furyl, phenyl, oxazolyl, isoxoxazolyl, imidazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, , 3,4-Thiadiazolyl, 1,2,4-Thiadiazolyl, 1,3,4-Thiadiazolyl, 1,2,4-Thiadiazolyl, pyridyl, pyranyl, pyragel, pyrimidinyl, pyridazinyl, 1,2,4-triazinyl , 1,2,3-triazinyl, 1,3,5_triazinyl, 1,2,5-oxathiazinyl, 1,2,6-oxathiazinyl, benzoxazolinole, benzothiazolyl, benzoimidazolyl,
- heteroarylthioalkyl specifically, 2-pyrrolylthiomethyl
- Examples thereof include 2-pyridylthiomethyl, 3-pyridylthiomethyl, 4-pyridylthiomethyl, and 2-chlorothiomethyl.
- the arylthioalkyl in R 1 and R 12 is preferably an alkyl moiety having 1 to 6 carbon atoms, which may be linear or branched, and the aryl moiety of the arylalkyl described above. This is the same as the reel section. Specific examples include phenylthiomethyl, 1-naphthylthiomethyl, 2-naphthylthiomethyl and the like.
- the alkylthioalkyl represented by R 1 and R 12 is the same as the above-mentioned alkyl in the alkylthio part, and the remaining alkyl part preferably has 1 to 6 carbon atoms and may be linear or branched. Specific examples include methylthiomethyl, ethylthiomethyl, n-propylthiomethyl, isopropylthiomethyl, n-butylthiomethyl, isobutylthiomethyl, sec_butylthiomethinole, tert-butylthiomethyl and the like.
- the arylalkylthioalkyl in R 1 and R 12 has the same arylalkyl moiety as the above arylalkyl.
- the remaining alkyl moiety preferably has 1 to 6 carbon atoms and may be linear or branched. Specifically, benzylthiomethyl, phenethylthiomethyl and the like can be mentioned.
- the alkyl part of the phthalimidalkyl in R 1 and R 12 is preferably 1 to 6 carbon atoms and may be linear or branched. Specifically, phthalimid-methyl, 2-phthalimid-ethyl and the like can be mentioned.
- the alkenyl in R 1 and R 12 preferably has 2 to 6 carbon atoms and includes, for example, butyl, aryl, 3-butenyl, 5-hexenyl and the like.
- the aryl in R 2 , R 1 ⁇ R 14 , R 15 , R 19 , R 20 , R 21 and R 23 is the same as the aryl moiety of the above arylalkyl, and is preferably phenyl.
- the A of one (CH 2 ), — A in R 1 and R 12 is an N-heterocycle linked by an N atom, and examples thereof include the following groups.
- R 8 and R 9 each represent hydrogen or together form another bond to form a double bond
- R 10 represents hydrogen, lower alkyl or phenyl
- X -CH CH (lower alkyl) one, — C (lower alkyl) one, -NH one, -N (lower alkyl) one or one O—
- Y ' is — O—
- — NH one or one N (Lower alkyl) represents one
- the lower alkyl may have 1 to 6 carbon atoms and may be linear or branched, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
- N-hetero ring examples include, for example, 2-oxo-11-pyrrolidinyl, 1-oxoisoindoline-1-yl, 2-oxoisoindoline-1-yl, and 2,5-dioxo _ 1-Pyrrolidinyl, 1,2-dimethyl-3,5-dioxo-1,2,4-triazolidin-4-yl, 2,5-dioxo-3-methyl-1-imidazolidinyl, 2,5-dioxo3, 4,4-trimethyl-1-imidazolidinyl, 3,5-dioxo-2-methyl-1,2,4-oxadiazolidine
- the heteroarylalkyl represented by R 2 , R 1 ⁇ R 14 , R 15 , R 19 , R 20 and R 23 means that the alkyl portion thereof preferably has 1 to 6 carbon atoms and may be linear or branched;
- the heteroaryl moiety is the same as the heteroaryl moiety of the above heteroarylthioalkyl.
- the cycloalkyl for R 2 preferably has 3 to 7 carbon atoms, for example, cycloalkyl
- the cycloalkylalkyl at R 2, the alkyl portions preferably may be a branched linear with carbon number 1-6, the cycloalkyl portion is the same as the consequent opening alkyl.
- Specific examples include cyclopropylmethyl, 2-cyclobutynoletinol, cyclopenty / lemethy / re, 3-cyclopentynolepropynole, cyclohexylmethyl, 2-cyclohexylethyl, cycloheptylmethyl and the like.
- the aromatic hydrocarbon ring for Q 1 and Q 2 is a benzene ring, a naphthalene ring, or an ortho-fused bicyclic hydrocarbon ring having from 8 to 10 ring atoms and at least one ring.
- aromatic rings for example, indene and the like
- it is a benzene ring.
- the aromatic hetero ring in Q 1 and Q 2 includes a 5- to 6-membered ring having a carbon atom and 1 to 4 hetero atoms (oxygen, sulfur or nitrogen), or an 8 to 10 ring derived therefrom. And a benzo derivative fused to an ortho-fused bicyclic aromatic hetero ring, particularly a benzene ring.
- aromatic heterocycle examples include pyrrole, furan, thiophene, oxazole, isoxazole, imidazoyl / re, thiazol, isothiazole, pyrazole, 1,2,3-triazole, 1,2,41 Triazole, tetrazol, 1,3,4-oxadiazole, 1,2,4-oxadiazole, 1,3,4-thiadiazole, 1,2,4-thiazazole, pyridine, pyrazine, pyrimidine, pyridazine, 1, 2,4-triazine, 1,2,3-triazine, 1,3,5-triazine, 1,2,5-oxathiazine, 1,2,6-oxathiazine, benzoxazol ⁇ , benzothiazol ⁇ benzimidazole , Tianaphthene, Isothianaphthene, Benzofuran, Isobenzofuran, Chromene, Isot
- the Heteroariru in R 1 6 and R 2 is similar to the Heteroariru portion of Teroari one Ruchioaruki Le to the, preferably pyridyl.
- arylalkyl, heteroarylthioalkyl, arylthioalkyl, arylalkylthioalkyl, phthalimidalkyl, aryl, heteroaryl and heteroarylalkyl are, for example, halogen (fluorine, chlorine, bromine, iodine), Hydroxyl group, nitro, cyano, trifluoromethyl, lower alkyl (but not substituted with alkyl moiety of arylalkyl, heteroarylrethioalkyl, arylthioalkyl, arylalkylthioalkyl, phthalimidalkyl) , Alkoxy, alkylthio, formyl, asiloxy, oxo, phenyl, aryl / leanolequinole, carboxyl, COO Ra (Ra represents lower alkyl, arylalkyl or aryl), a group represented by Le, Amino, lower Arukiruamino, di
- Alkoxy preferably has 1 to 6 carbon atoms and may be linear or branched. Examples thereof include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, and tert-butoxy.
- the alkylthio is preferably an alkyl moiety having preferably 1 to 6 carbon atoms and may be linear or branched, and examples thereof include methylthio, ethylthio, n-propylthio, and isopropylthio.
- the axyloxy is preferably an alkanoyloxy having 2 to 6 carbon atoms and which may be linear or branched, such as acetyloxy, propionyloxy, ptyryloxy, valeryloxy, bivaloyloxy, and hexanoyloxy.
- the arylalkyloxyalkyl has the same arylalkyl moiety as the above-mentioned arylalkyl, and the remaining alkyl moiety preferably has 1 to 6 carbon atoms and may be linear or branched. For example, benzyloxymethyl, phenethyloxymethyl and the like can be mentioned.
- the lower alkyl moiety in lower alkylamino and di-lower alkylamino is
- lower alkylamino examples include methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino, tert-butylamino, pentylamino, hexylamino and the like.
- di-lower alkylamino examples include dimethylamino, getylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di-sec-butylamino, di-tert-butylamino, dipentylamino, dihexylamino, and etino.
- Remethylamino methylpropylamino, butylmethylamino, ethylpropylamino, ethylbutylamino and the like.
- An optionally substituted heterocycle has a carbon atom and at least one nitrogen atom, and further contains at least one atom selected from nitrogen, oxygen and sulfur as a further heteroatom in the ring.
- a 4- to 7-membered ring group which may be substituted by oxo with respect to the carbon atoms constituting the ring, and further utilizes two adjacent carbon atoms constituting the heterocycle.
- an aromatic ring such as a benzene ring may be condensed.
- azetidino, 1-pyrrolidinyl, piperidino, 1-pirazurul, morpholino, thiomorpholino, oxothiomorpholino, dioxothiomorpholino, 2-oxo-11-quinazolinyl and the like can be mentioned.
- heterocycle contains a nitrogen atom as a further hetero atom such as 1-piperazinyl in the ring, a lower alkyl (as above), arylalkyl (as above), The group represented by heteroarylalkyl (same as above), aryl (same as above), heteroaryl (same as above), -COO Ra (Ra is the same as above), or acyl may be substituted.
- Preferred examples of the optionally substituted heterocycle include 1-pyrrolidinyl, piperidino, morpholino and 1-piperazinyl in which the nitrogen atom at the 4-position may be substituted by lower alkyl.
- R 3 is the formula (A)
- Q 1 represents a benzene ring
- m represents an integer of 0 to 3
- R 13 represents guanidino, hydroxysulfonyloxy, sulfo or a formula
- n represents an integer of 1 to 5
- r represents an integer of 0 to 2
- R 14 and R 15 may be the same or different Represents hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl, respectively, or R 14 and R 15 together with an adjacent nitrogen atom form a heterocycle which may be substituted.
- R 16 represents hydroxysulfonyloxy or sulfo)) or a group represented by
- R 19 and R 2 ° may be the same or different, and each represents hydrogen or alkyl.
- ⁇ reel alkyl indicates Heteroariru or Ariru
- R 19 Contact and R 2 ° may form a hetero cycle to which may be connexion substitutions together with the adjacent nitrogen atom
- R 21 is Ariru, Heteroariru , Hydroxysulfonyloxy, sulfo or carboxy
- Q 2 represents a furan ring
- R 18 represents arylalkyloxyalkyl or
- s and t may be the same or different, each represents an integer of 1 to 5, u represents an integer of 0 to 2, R 19 and R 2 are the same. Or hydrogen, alkyl, arylalkyl, heteroaryl or aryl, respectively, or R 19 and R 2 ° are substituted together with an adjacent nitrogen atom. may form a hetero cycles to good, R 22 represents a hydroxyl group, hydroxycarboxylic sulfonyl O alkoxy, a group represented by a group selected from sulfo or an carboxy)).
- R 3 has the formula (A)
- Q 1 represents a benzene ring
- m represents an integer of 0 to 3
- R 13 represents guanidino, hydroxysulfonyloxy, sulfo or a formula
- n represents an integer of 1 to 5
- r represents an integer of 0 to 2
- R 14 and R 15 may be the same or different , Respectively, hydrogen, alkyl, arylalkyl, heteroarylalkyl or aryl
- R 14 and R 15 may be taken together with an adjacent nitrogen atom to form an optionally substituted heterocycle, and R 16 represents hydroxysulfonyloxy or sulfo ))
- Y is furyl, phenyl, pyrrolyl, pyridyl, thiazolyl, phenyl, alkoxyphenyl, or —NR 19 R 2 ° (where R 19 and R 2 ° are the same or different And each represents an alkyl), or (ii) R 3 is alkyl or
- R 19 and R 2 ° may be the same or different, and each represents hydrogen
- R 19 and R 2 ° together with an adjacent nitrogen atom may form a heterocycle which may be substituted, R 21 and R 2 ° may represent an aryl, alkyl or heteroaryl or aryl; Represents aryl, heteroaryl, hydroxysulfonyloxy, sulfo or carboxy), or Q 2 represents a furan ring, and R 18 represents arylalkyloxyalkyl or
- R 19 and R 2 ° are the same.
- R 22 is a hydroxyl group, a hydroxycarboxylic sulfonyl O alkoxy, a group represented by a group selected from sulfo or an carboxy)).
- R 15 Represents a group represented by R 15 (wherein, n represents an integer of 1 to 5, r represents an integer of 1 or 2, R 14 and R 15 are the same or different and And each represents hydrogen or alkyl, or R 14 and R 15 may be taken together with an adjacent nitrogen atom to form a heterocycle which may be substituted.)
- Y is furyl, phenyl, pyrrolyl, pyridyl, thiazolyl, phenyl, alkoxyphenyl, or one NR 19 R 2 ° (wherein R 19 and R 2 may be the same or different, and This is a file substituted with.
- Q 1 represents a benzene ring
- m represents 1
- R 13 represents guanidino, hydroxysis / lephonyloxy, sulfo or a compound represented by the formula
- R 3 is alkyl or benzyl, and Y is
- R 19 and R 2 ° may be the same or different, and each represents hydrogen or
- R 38 May represent alkyl, or R 19 and R 2 ° together with an adjacent nitrogen atom may form an optionally substituted heterocycle, and R 21 represents phenyl or pyridyl) Shows the selected group.
- R 3 is alkyl or benzyl, and Y is of the formula
- R 19 and R 2 ° may be the same or different and each represents hydrogen or alkyl, or R 19 And R 2 ° together with the adjacent nitrogen atom form a heterocycle selected from 1-pyrrolidinyl, pyridino, morpholino and 1-piperazinyl in which the nitrogen atom at position 4 may be substituted with lower alkyl.
- R 21 represents phenyl or pyridyl).
- R 3 is alkyl or benzyl, and Y is of the formula
- R 19 and R 2 ° are the same.
- R 19 and R 2 ° together with an adjacent nitrogen atom may form a heterocycle which may be substituted, 22 is a group selected from the group consisting of:
- R 3 is alkyl or benzyl
- Y is
- s and t may be the same or different, each represents an integer of 1 to 5, u represents an integer of 0 or 1, and R 19 and R 2 ° are the same. Or may be different, and each represents hydrogen or alkyl, and R 22 represents a group selected from:
- Another preferred embodiment of the present invention includes the following.
- Preferred examples of the group represented by are those wherein Q 1 is a benzene ring, R 13 is hydrogen, guanidino, hydroxysulfonyloxy or
- R 15 A group represented by R 15 (wherein, n represents an integer of 1 to 5, r represents an integer of 0 to 2, and R 14 and R 15 may be the same or different. Often represents alkyl, or R 14 and R 15 may be taken together with an adjacent nitrogen atom to form an optionally substituted heterocycle). More preferred examples include groups where Q 1 is a benzene ring and R 13 is hydrogen.
- Preferred examples of the group represented by are those in which Q 2 is a benzene ring or an aromatic hetero ring selected from pyrrole, furan, thiophene, thiazole and pyridine, and R 18 is hydrogen or a formula
- Q 2 is a benzene ring or an aromatic hetero ring selected from pyrrol, furan, thiophene, thiazole and pyridine, and R 18 is hydrogen or a formula
- R represents an integer of 1 to 5
- u represents an integer of 0 to 2
- R 19 and R 2 ° may be the same or different.
- the protecting group for the hydroxyl group in X is, for example, arylalkyl (same as above), aryl (same as above), heteroaryl (same as above), silyl (for example, trimethylinoresilinole, tert-butinoresimethinoresilinole). Tert-butyldiphenylenosilyl), 2-tetrahydropyrael, p-methoxybenzyl, tert-butyl and the like.
- the arylalkyl, aryl and heteroaryl may have one or more substituents as exemplified above.
- silyl, 2-tetrahydrobiranyl, benzyl and the like are preferable.
- the hydroxamic acid derivative represented by the formula (I) or a pharmacologically acceptable salt thereof may have an asymmetric carbon, it may exist as an optically active form and a racemic form. Can be separated into each optically active substance by a method known per se.
- the hydroxamic acid derivative or a pharmacologically acceptable salt thereof further has an additional asymmetric carbon, the compound can exist as a diastereomer mixture or as a single diastereomer. These can also be separated from each other by a method known per se.
- hydroxamic acid derivative or a pharmacologically acceptable salt thereof is a polymorph.
- polymorphism can exist as more than one tautomer, and can exist as solvates (eg, ketone solvates, hydrates, etc.). it can.
- the present invention includes any stereoisomers, optical isomers, polymorphs, tautomers, solvates, and any mixtures thereof as described above.
- Optical isomers, racemates and diastereomers are also included in the scope of the present invention.
- the pharmacologically acceptable salts of the hydroxamic acid derivatives include, for example, alkali metal salts (eg, salts with lithium, sodium, potassium, etc.) and alkaline earth metal salts (eg, calcium, magnesium, etc.). Salts, aluminum salts, ammonium salts, salts with organic bases (eg, salts with triethylamine, morpholine, piperidine, triethanolamine, etc.).
- pharmacologically acceptable salts include, for example, inorganic acid addition salts (eg, salts with hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, etc.), organic acid addition salts
- a salt can be formed using oxalic acid.
- hydroxamic acid derivative represented by the formula (I) or a pharmacologically acceptable salt thereof the hydroxamic acid derivative wherein R 1 is phthalimidomethyl in the formula (I) or a pharmacologically acceptable salt thereof is preferable.
- n represents an integer of 1 to 5
- r represents an integer of 0 to 2
- R 14 and R 15 may be the same or different, and each represents hydrogen, alkyl, R 14 and R 15 may be taken together with an adjacent nitrogen atom to form an optionally substituted heterocycle
- R 16 represents arylalkyl, heteroarylalkyl or aryl; Represents a hydroxysulfonyloxy or a sulfo), a hydroxamic acid derivative which is benzyl which may be substituted with a substituent selected from the following, or a pharmacologically acceptable salt thereof.
- Preferred compounds include compounds 44, 84, 88, 91, 112, 115, 117, 120, 147, 152, 155, 191 194 and 245.
- Preferred compounds include compounds 44, 84, 88, 91, 112, 115, 117, 120, 147, 152, 155, 191 194 and 245.
- R 11 ' is R 11 as defined (provided that hydrogen is excluded), R 12' has the same meaning as R 1, R 1 R 2, R 3, X and Y are the as defined above ]
- the hydroxamic acid derivative of the present invention or a pharmacologically acceptable salt thereof is basically prepared by starting with a carboxylic acid (III) as an amino derivative.
- the intermediate compound (II ') is prepared by the C-terminal activation method in peptide synthesis [for example, basics and experiments on peptide synthesis (see Maruzen Shoten, Izumiya et al., ⁇ 91)].
- human Dorokishiruamin: X ⁇ 2 (X is as defined above) can be prepared by reaction with.
- amino derivative (IV) can be produced, for example, by the method described below.
- Step 1 is a step of preparing an intermediate compound (II ′) by reacting a carboxylic acid (III) with an amino derivative (IV).
- a typical method is shown below.
- Intermediate compound (II ') is obtained by reacting carboxylic acid (III) with isobutyl carbonate and amino derivative (IV) in the presence of an amine base such as triethylamine or N-methylmorpholine.
- an amine base such as triethylamine or N-methylmorpholine.
- a non-protonic solvent such as tetrahydrofuran (THF), methylene chloride, ethyl acetate, N, N-dimethylformamide (DMF) is used as a solvent, and the reaction can be performed at ⁇ 15 ° C. to room temperature.
- the acid chloride is once prepared by reacting the carboxylic acid (III) with oxalyl chloride or thionyl chloride.
- the solvent methylene chloride or a hydrocarbon-based solvent such as benzene or toluene is used, and the reaction is carried out at 15 ° C. to room temperature or under heating.
- the intermediate compound (II ′) can be obtained by reacting the obtained acid chloride with an amino derivative (IV) in the presence of an amine base such as triethylamine or pyridine.
- the solvent used is a non-protonic solvent such as THF, ethyl acetate, DMF, methylene chloride, benzene, toluene, etc., and should be used at 15 ° C to room temperature or under heating.
- Step 1-3 Method using DCC_HOB t method (coupling method)
- the intermediate compound (II ') is prepared by reacting carboxylic acid (III), amino derivative (IV) and 1-hydroxybenzotriazole (H ⁇ Bt) in the presence of an amine base such as triethylamine or N_methylmorpholine.
- an amine base such as triethylamine or N_methylmorpholine.
- a condensing agent such as 1,3-dicyclohexylcarbodiimide (DCC) or hexafluorophosphoric acid benzotriazo-1-yl 1-yloxytris (dimethylamino) phosphonium (BOP reagent) at a temperature below room temperature.
- Non-protonic solvents such as THF, methylene chloride, ethyl acetate, DMF and pyridine are used as the solvent.
- Step 1-1 Method using active ester method
- the active ester is once prepared by reacting a carboxylic acid (III) with a phenol derivative such as pentafluorophenol or a condensing agent such as DCC with N-hydroxysuccinic acid imid.
- a carboxylic acid (III) with a phenol derivative such as pentafluorophenol or a condensing agent such as DCC with N-hydroxysuccinic acid imid.
- the amine base is used as necessary, and examples of the amine base used include triethylamine and N-methylmorpholine.
- a non-protonic solvent such as THF, DMF, methylene chloride or the like is used, and the reaction is performed at a temperature lower than room temperature.
- the intermediate compound (II ′) can be obtained by reacting the obtained active ester with an amino derivative (IV).
- the amine base is used as needed, and examples of the amine base used include triethylamine or N-methylmorpholine.
- a solvent a non-protonic solvent such as THF, DMF, methylene chloride or the like is used, and the reaction can be performed at room temperature or lower.
- Step 2 is a step of converting the intermediate compound (II ′) into a succinic acid derivative (II ′′).
- the intermediate compound (II ') is reacted with a hydrogen chloride solution or trifluoroacetic acid to form a succinic acid derivative (II').
- a solvent an ether-based solvent such as 1,4-dioxane or methylene chloride is used, and the reaction can be performed at room temperature or lower.
- step 3 succinic acid derivative (II ′′) is converted to silyl (for example, trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, etc.), tert-butyl, benzyl, 2-tetrahydrobilanyl (Chem. Pharm. Bull. Jpn. 23, 167, 1975)
- This is a step of reacting a protected or unprotected hydroxylamine with a group or the like: XONH 2 (X is as defined above).
- the conditions in Step 1 can be applied.
- the protecting group of hydroxylamine can be removed under the same deprotection conditions as those for the protecting group at the hydroxyl group.
- the intermediate compound (II ′) can also be produced by the method shown in Scheme 2 below.
- Step 4 is a step of producing a compound (VI) by reacting a carboxylic acid (III) with an amino derivative (V). This step can be performed in the same manner as in step 1.
- amino derivative (V) can be produced, for example, by the method described below.
- Step 5 is a step of oxidizing compound (VI) to produce intermediate compound (II ′).
- the oxidation method include Moffatt oxidation, Swern oxidation, oxidation using Dess-Martin periodinane, Collins oxidation, and oxidation using manganese dioxide.
- the inert solvent used preferably includes halogenated hydrocarbon solvents such as methylene chloride and chloroform, and aromatic hydrocarbon solvents such as benzene, toluene and xylene.
- the reaction temperature, the raw materials used, but Ru different by oxidation or the like usually - a 7 8 ⁇ 5 0 Q C.
- the reaction time varies depending on the starting materials used, the oxidation method and the like, but is usually 30 minutes to 24 hours.
- Introduction of the desired substituent R 1 can be carried out by using the carboxylic acid (III) having the substituent by the method shown in the above scheme 1 or scheme 2 without going through any special steps. However, for example, it can also be performed by the method shown in the following scheme 3.
- R 1 is heteroarylthioalkyl, arylthioalkyl, alkyl
- Step 6 is a step in which an intermediate compound (II′a) is obtained using carboxylic acid (VII) as a raw material in the same manner as in step 1 of scheme 1 above.
- the carboxylic acid (VII) as a raw material is a compound described in a literature (Japanese Patent Application Laid-Open No. 7-157470) or a compound prepared by a conventional method based on these literatures. It is.
- Step 7 is a step of removing the substituents R 1 ⁇ and R 23 ′ in the intermediate compound (II′a) to obtain a succinic acid derivative (II ′′ a).
- the reaction can be carried out at normal pressure or under pressure by a usual catalytic hydrogenation reaction in the presence of a metal catalyst.
- the metal catalyst palladium carbon or palladium black can be used, and the solvent may be an ether solvent such as 1,4-dioxane, an ester solvent such as ethyl acetate, or an alcohol solvent such as methanol, ethanol or isopropyl alcohol. It can be used at room temperature and under heating.
- Step 8 is a step of converting the succinic acid derivative (II "a) obtained in step 7 to a succinic acid derivative (II" b) which is a monocarboxylic acid by decarboxylation.
- a hydrocarbon solvent such as xane, benzene, or toluene is used, and the reaction can be performed at room temperature or under heating in the presence of a tertiary amine such as N-methylmorpholine or triethylamine.
- step 9 the succinic acid derivative (II "a) obtained in step 7 is reacted with formaldehyde in the presence of a secondary amine to obtain a succinic acid derivative (II") which is ⁇ -exomethylene carboxylic acid. c) piperidine as secondary amine,
- step 10 the succinic acid derivative (II''c) obtained in step 9 is reacted with arylthiothiol, heteroarylthiol, alkynolethiol or arylalkylthiol as a nucleophile.
- This is a step of obtaining a succinic acid derivative (II ′′ d) in which the substituent R 1 is arylthioalkyl, heteroarylthioalkyl, alkylthioalkyl or arylalkylthioalkyl.
- This reaction can be carried out without a solvent or in a halogenated hydrocarbon solvent such as methylene chloride, an alcohol solvent such as methanol, or an amide solvent such as DMF under heating from room temperature.
- amino derivative (IV) and the amino derivative (V) which are the starting compounds in the schemes 1 to 3 can be produced by the method shown in the following scheme 4.
- a ′ represents an amino protecting group such as tert-butoxycarbonyl or benzyloxycarbonyl
- M represents lithium or 1 Mg P 1 (P 1 represents a halogen such as bromine or chlorine)
- Y represents 2-thiazolyl or 2-oxazolyl which may be substituted with lower alkyl or phenyl
- R 3 and Y are as defined above.
- Step 11 is a step of reacting compound (i) with 0, N-dimethylhydroxylamine hydrochloride in an inert solvent in the presence of a condensing agent and a base to produce compound (ii).
- This step can be performed by a general method described in Jean-Alain Fehrentz et al. Synthesis (1983) p. 676-678.
- Step 12 is a step of reacting the compound (i ⁇ ) with the organometallic compound YM to produce the compound (iii).
- the inert solvent used is preferably hexane or cyclohexane. Examples thereof include aliphatic hydrocarbon solvents such as xane and ether solvents such as getyl ether and tetrahydrofuran.
- the reaction temperature is usually ⁇ 78 to 80 ° C., preferably 178 to 40 ° C.
- the reaction time varies depending on the starting material used, the solvent, the reaction temperature and the like, but is usually 15 minutes to 24 hours, preferably 15 minutes to 10 hours.
- Step 13 is a step of producing an amino derivative (IV) by deprotecting the protecting group of the amino group of the compound (iii).
- the protecting group A ′ is a t tert -butoxycarbonyl group
- it can be removed under acidic conditions such as trifluoroacetic acid, hydrogen chloride-containing dioxane, hydrogen chloride-containing methanol, and hydrogen bromide-containing acetic acid.
- inert solvents used include halogenated hydrocarbon solvents such as methylene chloride and chloroform, ether solvents such as getyl ether, tetrahydrofuran and dioxane, methanol, ethanol, n-propyl alcohol, and isopropyl alcohol.
- Alcohol solvents such as alcohol, organic acids such as acetic acid
- the reaction temperature is generally 0 to 100 ° C, preferably 0 to 50 ° C.
- the reaction time is generally 15 minutes to 12 hours, preferably 15 minutes to 4 hours.
- the protecting group A ' is a benzyloxycarbonyl group
- a method of removing the protecting group by treatment with an acid or a method of removing the protecting group by catalytic reduction is preferable.
- the acid used in the acid method trifluoromethanesulfonic acid is preferred.
- the solvent used is preferably methylene chloride.
- the reaction temperature and reaction time are preferably from 0 to 50 ° C for 5 minutes to 6 hours.
- the catalyst used in the catalytic reduction method preferably includes palladium carbon / palladium black.
- Suitable solvents include alcohol solvents such as methanol, ethanol, n-propyl alcohol, and isopropyl alcohol; ether solvents such as ethyl ether, tetrahydrofuran and 1,4-dioxane; and ester solvents such as ethyl acetate. It is.
- the pressure of hydrogen is usually 1 to 10 atm, and the reaction temperature and reaction time are preferably 0 to 100 ° C and 5 minutes to 24 hours.
- Step 14 is a step of reducing compound (ii) with a reducing agent such as lithium aluminum hydride in an inert solvent to produce compound (iv).
- a reducing agent such as lithium aluminum hydride in an inert solvent to produce compound (iv).
- This step can be performed by the general method described in the above-mentioned Jean-Alain Fehrentz et al. Synthesis (1983) p.676-678.
- Step 15 comprises (a) the reaction of the compound (iV) with the organometallic compound Y-M in an inert solvent, or (b) the compound (iV) in an inert solvent with a trimethylsilyl derivative [ Y "— S i (CH 3 ) 3 ] (however, Y" is limited to 2-thiazolyl or 2-oxazolyl which may be substituted by lower alkyl or phenyl) to give the compound ( V).
- 2-methyltrilinylthiothiazole which may be substituted with lower alkyl or phenyl, which is a trimethylsilyl derivative, is obtained from Alessandro Dondoni et al., J. Org. Chem. (1988) 53 ⁇ ⁇ 1748-1761, which may be substituted by lower alkyl or phenyl, 2-trimethylsilyloxazole is described by Alessandro Dondoni et al. Org. Chem. (1987) 52 p. 3413-3420.
- the reaction is preferably carried out without solvent or in methylene chloride.
- the reaction temperature is usually ⁇ 40 to 80 ° C., and preferably ⁇ 20 to 40 ° C.
- the reaction time varies depending on the starting material, solvent, reaction temperature and the like used, but is usually 1 to 48 hours, preferably 1 to 24 hours.
- the target compound After completion of the reaction, if no solvent is used, dilute with THF, react with tetrabutylammonium fluoride at room temperature for 1 to 2 hours, and perform post-treatment according to a conventional method to obtain the target compound. it can.
- the target compound In the case of a reaction using a solvent, the target compound can be obtained by performing the above-mentioned operations after the reaction is completed and after distilling off the solvent.
- the reaction is preferably carried out without solvent or in benzene, toluene or xylene.
- the reaction temperature is usually 0 to 150 ° C, preferably 20 to 100 ° C.
- the reaction time varies depending on the starting material, solvent, reaction temperature and the like to be used, but is usually 1 to 80 hours, preferably 1 to 50 hours.
- the target compound can be obtained in the same manner as in the case where 2-trimethylsilylthiazole is used.
- the target compound can be obtained by reacting with 1 to 2 N hydrochloric acid instead of tetrabutylammonium fluoride for 0.5 to 2 hours and performing post-treatment according to a conventional method.
- Step 16 is a step of producing an amino derivative (V) by deprotecting the protecting group of the amino group of compound (v), and can be carried out in the same manner as in step 13.
- Z represents lower alkyl such as methyl or ethyl or arylalkyl such as benzyl, and A ′, M, R 3 and Y are as defined above]
- Step 17 is a step of producing compound (V i) by reacting compound (i) with alcohol ZOH in the presence of a condensing agent.
- a condensing agent examples include halogenated hydrocarbon solvents such as methylene chloride and chloroform, ester solvents such as ethyl acetate, ether solvents such as getyl ether, tetrahydrofuran, and 1,4-dioxane.
- the solvent include methylene chloride and tetrahydrofuran.
- Preferred examples of the condensing agent include DCC, 1- (3-dimethylaminopropyl) -13-ethylcarposimidide, diphenylphosphoryl azide and the like.
- a deoxidizing agent may be used in combination in the present reaction, and the deoxidizing agent used is preferably triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, or 4-dimethylamino.
- the deoxidizing agent used is preferably triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, or 4-dimethylamino.
- organic amines such as pyridine, 4-pyrrolidinopyridine and proton sponge.
- the reaction temperature is usually 0 to 80 ° C, preferably 0 to 40 ° C.
- the reaction time varies depending on the starting material, solvent, reaction temperature and the like to be used, but is usually 1 to 48 hours, preferably 1 to 12 hours.
- Step 18 is a step of reacting the compound (V i) with the organometallic compound YM to produce the compound (ii i), and can be performed in the same manner as in step 12.
- Process 1 9
- Step 19 is a step of producing compound (i V) by reducing compound (V i) using a reducing agent such as diisobutylaluminum hydride. This step can be performed by the method described in Daniel H. Rich et al., J. Org. Chem. (1978) 43 p. 3624-3626.
- the organometallic compound Y-M used in the above reaction is a compound represented by the formula: Y-U (U represents hydrogen or halogen, and Y is as defined above). It can be prepared by reacting with aryl lithium or Grignard reagent.
- Examples of the alkyl lithium used include ethyl lithium, n-butyl lithium, sec-butyl lithium, tert-butyl lithium, and the like.
- Examples of aryllithium include phenyllithium, and examples of Grignard reagents include methylmagnesium bromide.
- the solvent used, the reaction temperature and the reaction time are the same as those in Step 12.
- the starting compound (i) in Schemes 4 and 5 can be produced by the following method.
- amino group of the amino acid represented by is protected with an amino-protecting group such as a tert-butoxycarbonyl group or a benzyloxycarbonyl group (for example, basic and experimental peptide synthesis (see Maruzen Shoten, Izumiya et al., P16)) Can be prepared.
- an amino-protecting group such as a tert-butoxycarbonyl group or a benzyloxycarbonyl group (for example, basic and experimental peptide synthesis (see Maruzen Shoten, Izumiya et al., P16)) Can be prepared.
- the hydroxamic acid derivative of the present invention synthesized in this manner can be purified to an arbitrary purity by appropriately performing known separation and purification means, for example, concentration, extraction, chromatography, reprecipitation, and recrystallization. It can be collected as something.
- pharmacologically acceptable salts and solvates of the hydroxamic acid derivative can be produced by a known method.
- various isomers of the hydroxamic acid derivative can also be produced by a known method.
- hydroxamic acid derivative of the present invention and a pharmacologically acceptable salt thereof are provided.
- the hydroxamic acid derivative of the present invention and a pharmacologically acceptable salt thereof are useful as inhibitors of TNF production, and include, for example, sepsis, MOF, rheumatoid arthritis, Crohn's disease, cachexia, skeletal muscle It is useful for preventing and treating diseases such as asthenia, systemic lupus erythematosus, asthma, type I diabetes, psoriasis, other autoimmune diseases, and inflammatory diseases.
- the hydroxamic acid derivative of the present invention and its pharmacologically acceptable salt are used as pharmaceuticals, granules, tablets, capsules, injections, ointments, ophthalmic drops, and pharmacologically acceptable carriers are used. It can be orally or parenterally administered as a pharmaceutical composition in the form of a nasal solution, cream, aerosol or the like.
- the hydroxamic acid derivative and its pharmacologically acceptable salt are excellent in water solubility, they are suitable for preparing water-soluble pharmaceutical compositions such as injections, eye drops, nasal drops, and infusions. preferable.
- An effective amount of the hydroxamic acid derivative and a pharmacologically acceptable salt thereof is added to the above preparation.
- the dose of the hydroxamic acid derivative and a pharmacologically acceptable salt thereof varies depending on the administration route, the patient's condition, body weight, age, and the like, and can be appropriately set depending on the purpose of administration. Usually, when administered orally to an adult, it is preferable to administer 0.01 to 1,000 mg / kg body weight Z day, preferably 0.05 to 250 mg Zkg body weight / day, in 1 to several times a day. .
- H-NMR was measured at 300 or 50 OMHz.
- One NMR chemical shift used tetramethylsilane as an internal standard and expressed relative delta ( ⁇ ) values in parts permillion (ppm). Coupling constants indicate trivial multiplicity in Hertz (Hz), s (singlet), d (doublet), t (t
- Example 2 The title compound (4. 3 0 g, 9.97 discussions ol) of Example 1 (3) to a solution in methylene chloride (20 ml), added Torifuruoro acetate (20 ml) under ice cooling, the temperature For 30 minutes. The reaction solution was concentrated and crystallized from diethyl ether to obtain the title compound (3.64 g, 82%) as a white solid.
- the title compound (3.60 g, 8.08 mmol) of (4) in Example 1 was prepared according to the method described in JP-A-4-352757 34-tert-470 Butoxy 2 (R) -isobutyl-3 (or) -phthalimid-methylsuccinic acid (3.15 g, 8.08 ol), 1-hydroxybenzotriazole monohydrate (HOB t.H 20 ) (1.24 g, 8.08 mmol) ) And N-methylmorpholine (2.70 ml, 24.2 tnmol) were dissolved in DMF (80 ml), BOP reagent (5.36 g, 12.1 mmol) was added under ice-cooling, and the mixture was stirred at room temperature for 6 hours.
- the BOP reagent (154 rag, 0.35 ol) was added under ice cooling, and the mixture was stirred at room temperature for 13 hours.
- Water (50 ml) was added to the reaction solution, and extracted with ethyl acetate (2 ⁇ 50 ml).
- the organic layer was washed successively with a saturated aqueous sodium hydrogen carbonate solution (2 ⁇ 50 ml) and a saturated saline solution (50 ml), dried over anhydrous sodium sulfate and concentrated.
- the obtained residue was purified by silica gel column chromatography (20: 1 chloroform-methanol) to give the title compound (120 mg, 66%) as a white solid.
- Example 2 To a solution consisting of the title compound of (9) in Example 1 (110 rag, 0.14 mmol), methylene chloride (10 ml) and methanol (10 ml) was added 1.3 N hydrogen chloride-methanol reagent under ice cooling. (1 ml) was added and the mixture was stirred at room temperature for 2 hours. The reaction mixture was added with diethyl ether to precipitate a solid, and the title compound (69 mg, 62%) was obtained as a white solid.
- Example 1 68 Minoetokishi phenyl] - 3-phenylene Lou 1 - according to the method of the propanone Example 1 (3), the title compound and New alpha of Example 2 (1) - (tert-butoxycarbonyl) Single L one-phenylene Ruaranin Reacted with N-methoxy N-methylamide, purified by silica gel column chromatography (100: 1 chloroform-methanol), and recrystallized from hexane to give a white solid The title compound (15% yield) was obtained.
- Example 2 The title compound of Example 2, (2) was treated in the same manner as in Example 1, (4) to quantitatively obtain the title compound as a yellow viscous oil.
- Example 2 The title compound of Example 2 (4) was treated in the same manner as in Example 1 (8) and crystallized with getyl ether to give the title compound as a white solid.
- Example 2 The title compound of (6) of Example 2 was treated in the same manner as (10) of Example 1 and crystallized from ethyl ether to give the title compound (86% yield) as a white solid. .
- Example 3 The title compound of Example 3, (4) was treated in the same manner as in Example 1, (4) and crystallized from getyl ether to give the title compound (yield 89%) as a white solid.
- Example 3 The title compound of Example 3, (6) was treated in the same manner as in Example 1, (8) and crystallized from getyl ether to give the title compound (79% yield) as a white solid.
- Example 3 In the same manner as in Example 1, (9), the title compound of Example 3 (7) was reacted with O-2-tetrahydrodrobilanylhydroxylamine, and the reaction solution was added with water (50 ml) under ice-cooling. ) -Jetyl ether (50 ml) was added. The precipitated solid was collected by filtration, washed successively with water, a saturated aqueous solution of sodium hydrogencarbonate, water and getylether, and dried to obtain the title compound (75% yield) as a white solid.
- the title compound (280 mg, 8%) was obtained as a reddish-brown liquid by purifying with (20: 1 black-mouthed form-methanol).
- Example 4 (2) The title compound of Example 4 (2) was treated in the same manner as in Example 1 (4) to quantitatively obtain the title compound as a red oil.
- Example 4 The title compound of Example 4 (4) was treated in the same manner as in Example 1 (8) to give the title compound (98% yield) as an amorphous solid.
- Example 79 In the same manner as in Example 1, (9), the title compound of Example 4, (5) was reacted with O-2-tetrahydrodrobilanylhydroxylamine, and the mixture was subjected to silica gel column chromatography (10: 1 chromatography). The title compound was obtained as an amorphous solid (yield 47%).
- Example 4 The title compound of (6) in Example 4 was treated in the same manner as (10) in Example 1 and crystallized with ethyl ether to give the title compound (63% yield) as a white solid.
- Example 5 (2) The title compound of Example 5 (2) was treated in the same manner as in Example 1 (4) and crystallized from getyl ether-hexane to give the title compound quantitatively as a brown solid.
- Example 5 The title compound of (5) of Example 5 was subjected to catalytic hydrogenation in the same manner as (6) of Example 1 and purified by silica gel column chromatography (50: 1 1: 1 chloroform-methanol). As a result, the title compound (yield 49%) was obtained as an amorphous solid.
- Example 5 The title compound of (5) of Example 5 was reacted with 2-dimethylaminoethanol in the same manner as in (7) of Example 1, and the mixture was subjected to silylation gel column chromatography (20: 1 chloroform-methanol). The title compound was obtained as an amorphous solid.
- Example 5 By treating the title compound of Example 5 (6) in the same manner as in Example 1 (8), the title compound was obtained as an amorphous solid.
- Example 5 In the same manner as in Example 1, (9), the title compound of Example 5, (7) was reacted with O-2-tetrahydrodrobilanylhydroxylamine, and silica gel column chromatography was performed.
- Example 5 The title compound of (8) in Example 5 was treated in the same manner as (10) in Example 1, and getyl ether was added to the reaction solution, and the precipitated solid was collected by filtration.
- the obtained solid was purified by reversed-phase column chromatography (Fuji Silysia Chemical Chromatorex ODS DM-1020T; 17-33% acetonitrile-0.1% trifluoroacetic acid aqueous solution) and freeze-dried. To the obtained residue was added 0.1 N hydrochloric acid (20 ml), followed by freeze-drying again to obtain the title compound (164 mg, 45%) as an amorphous solid.
- Example 6 The title compound of Example 6, (1) was subjected to catalytic hydrogenation reaction in the same manner as in Example 1, (6), and purified by silica gel column chromatography (1: 1 ethyl hexane monoacetate). As a result, the title compound (yield 62%) was obtained as an amorphous solid.
- Example 6 The title compound of Example 6, (2) was treated in the same manner as in Example 1, (8), and recrystallized from getyl ether-hexane to give the title compound as a white solid (yield 87%). .
- Example 6 In the same manner as in Example 1, (9), the title compound of Example 6, (3) was reacted with O-2-tetrahydrodrobilanylhydroxylamine, and the mixture was subjected to silica gel column chromatography. The title compound was obtained as a white solid (yield 75%) by purification with form-methanol.
- a pyridine-sulfur trioxide complex (370 mg, 2.32 mmol) was added to a solution of the title compound of Example 6 (4) (500 mg, 0.77 mmol) dissolved in DMF (3 ml) under ice cooling. The mixture was stirred at room temperature for 2 hours. Next, a 1 N aqueous solution of sodium hydrogen carbonate (20 ml) was added to the reaction solution, and the mixture was stirred at room temperature for 30 minutes. The reaction solution was purified by reversed-phase column chromatography (Fuji Silysia Chemical Chromatorex ODS DM-1020T; 0-50% aqueous methanol solution), and lyophilized to give the title compound (528 mg, 91%).
- reaction solution was added to 1N hydrochloric acid (140 ml) saturated with sodium chloride, the organic layer was separated from the aqueous layer, and the aqueous layer was extracted with THF (2 ⁇ 200 ml). The organic layer and the THF layer were combined, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel column chromatography (10: 1 formaldehyde methanol) to give the title compound (6.65 g, 93%) as a brown oil.
- the mixture was washed successively with a 2: 1 mixed solution of 1 N hydrochloric acid, a saturated aqueous solution of sodium hydrogen carbonate and saturated saline, and saturated saline, dried over anhydrous magnesium sulfate, and concentrated.
- the residue was purified by silica gel column chromatography (10: 1 chloroform-methanol) to give the title compound (96% yield) as a pale yellow foam.
- Example 7 In the same manner as in Example 1, (8), the title compound of Example 7, (5) was dissolved in trifluoroacetic acid and stirred at room temperature for 1.5 hours. After concentration of the reaction solution, getyl ether was added to the residue to give a powder, and the title compound (quantitative) was obtained as a pale green powder.
- reaction solution was diluted with THF, washed successively with a 2: 1 mixed solution of a saturated aqueous solution of sodium hydrogencarbonate and saturated saline, and saturated saline, dried over anhydrous magnesium sulfate, and concentrated. The residue was triturated with geethylether to give the title compound (quantitative) as a pale yellow powder.
- Example 7 The title compound of Example 7, (7) was treated in the same manner as in Example 6, (6), and purified by reversed-phase column chromatography (Fuji Silicon Chemicals Chromatorex ODS DM-1020T; 0 to 25% aqueous methanol). Thereafter, the mixture was concentrated and powdered by adding getyl ether to obtain the title compound (yield 16%) as a white powder.
- JP-A No. 4-352,757 discloses a method prepared in accordance with the method described in JP-A-7-157474.
- Example 11 A mixture of the title compound of (1) in Example 11 (12.2 g, 25.4 mol), Lawesson's reagent (3.00 g, 7.41 mmol) and toluene (100 ml) was stirred under reflux for 2.5 hours. Then, the mouth-mouth reagent (2.66 g, 6.58 mmol) was added, and the mixture was stirred under reflux for 1.5 hours. The reaction solution was returned to room temperature, and purified as it was by silica gel column chromatography-(25: 1 ethyl hexane monoacetate) to obtain the title compound (6.17 g, 49%) as a reddish brown liquid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002332946A CA2332946A1 (en) | 1998-05-22 | 1999-05-19 | Hydroxamic acid derivative and pharmaceutical use thereof |
EP99921188A EP1081132B1 (en) | 1998-05-22 | 1999-05-19 | Hydroxamic acid derivatives and medicinal utilization thereof |
DE69915467T DE69915467T2 (de) | 1998-05-22 | 1999-05-19 | Hydroxamsäurederivate und ihre medizinische anwendung |
US09/701,043 US6610729B1 (en) | 1998-05-22 | 1999-05-19 | Hydroxamic acid derivatives and medicinal utilization thereof |
AT99921188T ATE261428T1 (de) | 1998-05-22 | 1999-05-19 | Hydroxamsäurederivate und ihre medizinische anwendung |
AU38496/99A AU3849699A (en) | 1998-05-22 | 1999-05-19 | Hydroxamic acid derivatives and medicinal utilization thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/141304 | 1998-05-22 | ||
JP14130498 | 1998-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999061412A1 true WO1999061412A1 (fr) | 1999-12-02 |
Family
ID=15288785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/002631 WO1999061412A1 (fr) | 1998-05-22 | 1999-05-19 | Derives d'acide hydroxamique et utilisation medicinale de ces derives |
Country Status (10)
Country | Link |
---|---|
US (1) | US6610729B1 (ja) |
EP (1) | EP1081132B1 (ja) |
KR (1) | KR100606989B1 (ja) |
CN (1) | CN1289472C (ja) |
AT (1) | ATE261428T1 (ja) |
AU (1) | AU3849699A (ja) |
CA (1) | CA2332946A1 (ja) |
DE (1) | DE69915467T2 (ja) |
ES (1) | ES2214026T3 (ja) |
WO (1) | WO1999061412A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1306367A1 (en) * | 2000-07-19 | 2003-05-02 | Welfide Corporation | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
WO2005037265A1 (ja) * | 2003-10-17 | 2005-04-28 | Mitsubishi Pharma Corporation | 併用薬剤 |
US7521563B2 (en) | 2004-08-10 | 2009-04-21 | Shizuoka Coffein Co., Ltd. | Hydroxamic acid derivative and medicine containing the same as active ingredient |
JP2009529523A (ja) * | 2006-03-09 | 2009-08-20 | オーエム ファーマ | 免疫調節化合物、及び炎症性サイトカインの過剰産生に関連する疾患の治療 |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000061134A1 (en) * | 1999-04-09 | 2000-10-19 | British Biotech Pharmaceuticals Limited | Antimicrobial agents |
US20050124684A1 (en) * | 2003-08-29 | 2005-06-09 | Ying Du | 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08505605A (ja) * | 1992-11-13 | 1996-06-18 | ブリテッシュ バイオテック ファーマシューティカルズ リミテッド | Tnf産生の阻害剤 |
WO1998030541A1 (en) * | 1997-01-07 | 1998-07-16 | Abbott Laboratories | C-terminal ketone hydroxamic acid inhibitors of matrix metalloproteinases and tnfa secretion |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985911A (en) * | 1997-01-07 | 1999-11-16 | Abbott Laboratories | C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion |
-
1999
- 1999-05-19 AT AT99921188T patent/ATE261428T1/de not_active IP Right Cessation
- 1999-05-19 KR KR1020007013151A patent/KR100606989B1/ko not_active IP Right Cessation
- 1999-05-19 DE DE69915467T patent/DE69915467T2/de not_active Expired - Fee Related
- 1999-05-19 CA CA002332946A patent/CA2332946A1/en not_active Abandoned
- 1999-05-19 ES ES99921188T patent/ES2214026T3/es not_active Expired - Lifetime
- 1999-05-19 EP EP99921188A patent/EP1081132B1/en not_active Expired - Lifetime
- 1999-05-19 AU AU38496/99A patent/AU3849699A/en not_active Abandoned
- 1999-05-19 CN CNB998090336A patent/CN1289472C/zh not_active Expired - Fee Related
- 1999-05-19 WO PCT/JP1999/002631 patent/WO1999061412A1/ja active IP Right Grant
- 1999-05-19 US US09/701,043 patent/US6610729B1/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08505605A (ja) * | 1992-11-13 | 1996-06-18 | ブリテッシュ バイオテック ファーマシューティカルズ リミテッド | Tnf産生の阻害剤 |
WO1998030541A1 (en) * | 1997-01-07 | 1998-07-16 | Abbott Laboratories | C-terminal ketone hydroxamic acid inhibitors of matrix metalloproteinases and tnfa secretion |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1306367A1 (en) * | 2000-07-19 | 2003-05-02 | Welfide Corporation | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
EP1306367B1 (en) * | 2000-07-19 | 2007-07-18 | Mitsubishi Pharma Corporation | Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
WO2005037265A1 (ja) * | 2003-10-17 | 2005-04-28 | Mitsubishi Pharma Corporation | 併用薬剤 |
US7521563B2 (en) | 2004-08-10 | 2009-04-21 | Shizuoka Coffein Co., Ltd. | Hydroxamic acid derivative and medicine containing the same as active ingredient |
JP2009529523A (ja) * | 2006-03-09 | 2009-08-20 | オーエム ファーマ | 免疫調節化合物、及び炎症性サイトカインの過剰産生に関連する疾患の治療 |
US8618080B2 (en) | 2006-03-09 | 2013-12-31 | Om Pharma | Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Also Published As
Publication number | Publication date |
---|---|
ATE261428T1 (de) | 2004-03-15 |
DE69915467D1 (de) | 2004-04-15 |
CN1310704A (zh) | 2001-08-29 |
CA2332946A1 (en) | 1999-12-02 |
DE69915467T2 (de) | 2005-01-27 |
AU3849699A (en) | 1999-12-13 |
EP1081132A1 (en) | 2001-03-07 |
EP1081132A4 (en) | 2002-11-13 |
CN1289472C (zh) | 2006-12-13 |
KR100606989B1 (ko) | 2006-08-01 |
EP1081132B1 (en) | 2004-03-10 |
KR20010043767A (ko) | 2001-05-25 |
US6610729B1 (en) | 2003-08-26 |
ES2214026T3 (es) | 2004-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU617429B2 (en) | Amino acid derivatives | |
EP2430006B1 (fr) | Dérivés de cyclopenta[c]pyrrole-2-carboxylates, leur préparation et leur application en thérapeutique | |
ES2236829T3 (es) | Acidos beta-sulfonil hidroxamicos como inhibidores de las metaloproteinas de la matriz. | |
US20020103192A1 (en) | Inhibitors of histone deacetylase | |
WO1996005169A1 (fr) | Derive d'acide amique n,n-bisubstitue | |
HRP20030748A2 (en) | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | |
JPH04308574A (ja) | レトロウイルス阻害性化合物 | |
RO115354B1 (ro) | Compusi fenilheterociclici, procedee pentru prepararea acestora, intermediar de preparare, compozitie farmaceutica si metoda pentru tratamentul unei afectiuni inflamatorii | |
AU2002359376A1 (en) | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives | |
EP1453789A2 (en) | N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives | |
WO2008038768A1 (fr) | Composé ayant une structure de pyrimidine bicyclique et composition pharmaceutique comprenant le composé | |
JP2006028193A (ja) | N−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 | |
AU750019B2 (en) | Aryl alkanoylpyridazines | |
EP2429998B1 (fr) | Dérivés de cyclopenta[c]pyrrolylalkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique | |
FR2941696A1 (fr) | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique | |
WO2002018321A2 (en) | Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors | |
WO1999061412A1 (fr) | Derives d'acide hydroxamique et utilisation medicinale de ces derives | |
WO1990005132A1 (en) | Substituted allylamine derivatives, process for their preparation and their use | |
JP2003505367A (ja) | マトリックスメタロプロテイナーゼ阻害剤としての3−アリールスルホニル−2−(置換メチル)プロパン酸誘導体 | |
JP4373343B2 (ja) | ペプチドデホルミラーゼ阻害剤 | |
US6596738B1 (en) | Heterocyclic compound, composition and method for inhibiting adenosine deaminase | |
JP3490441B2 (ja) | レニン阻害剤としてのn−(ヒドロキシエチル)ブタンジアミド誘導体 | |
JPH03173865A (ja) | 置換アリルアミン誘導体、その製造法及びその用途 | |
WO1997017321A1 (fr) | Derives cycliques d'acide amique | |
WO1995018121A1 (fr) | Nouveau derive de benzylamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99809033.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref document number: 2332946 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007013151 Country of ref document: KR Ref document number: 09701043 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999921188 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999921188 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007013151 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999921188 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007013151 Country of ref document: KR |